William R Wilson Selected Research

Phosphates (Orthophosphate)

1/2018	Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.
9/2015	AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
1/2013	The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
6/2011	Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
3/2011	Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins.
3/2010	Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans.
10/2007	Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
9/2007	Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
9/2007	Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William R Wilson Research Topics

Disease

77	Hypoxia (Hypoxemia) 03/2024 - 12/2002
56	Neoplasms (Cancer) 06/2022 - 03/2002
6	Squamous Cell Carcinoma of Head and Neck 03/2024 - 01/2018
4	Leukemia 09/2015 - 01/2011
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2015 - 01/2011
3	Body Weight (Weight, Body) 01/2022 - 01/2003
3	Carcinoma (Carcinomatosis) 02/2005 - 01/2004
2	Thrombosis (Thrombus) 06/2024 - 02/2021
2	Hypersensitivity (Allergy) 10/2020 - 06/2009
2	Infections 01/2019 - 10/2011
2	Hypothermia 01/2019 - 01/2017
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 09/2015 - 03/2014
2	Hepatocellular Carcinoma (Hepatoma) 01/2015 - 08/2011
2	Thrombocytopenia (Thrombopenia) 10/2011 - 08/2011
1	Head and Neck Neoplasms (Head and Neck Cancer) 03/2024
1	Rupture 06/2022
1	Breast Neoplasms (Breast Cancer) 10/2020
1	Acidosis 07/2019
1	Necrosis 10/2018

Drug/Important Bio-Agent (IBA)

63	ProdrugsIBA 03/2024 - 03/2002
22	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2004
22	Oxidoreductases (Dehydrogenase)IBA 10/2020 - 09/2007
21	PR-104AIBA 01/2018 - 07/2007
20	Tirapazamine (SR 4233)IBA 01/2017 - 01/2003
20	PR-104IBA 09/2015 - 07/2007
16	Oxygen (Dioxygen)IBA 12/2021 - 06/2004
15	Cytotoxins (Cytolysins)IBA 05/2016 - 01/2004
14	CEN-209IBA 01/2019 - 10/2010
10	Biomarkers (Surrogate Marker)IBA 03/2024 - 05/2009
9	TH 302IBA 01/2023 - 12/2013
9	Phosphates (Orthophosphate)IBA 01/2018 - 09/2007
9	Alkylating AgentsIBA 07/2013 - 09/2004
8	OxidesIBA 07/2019 - 09/2003
7	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2018 - 04/2003
7	Aldo-Keto ReductasesIBA 01/2017 - 03/2010
7	EstersIBA 09/2015 - 09/2007
5	NADPH-Ferrihemoprotein Reductase (Cytochrome P450 Reductase)IBA 10/2020 - 06/2007
5	Hydroxylamine (Hydroxylamine Hydrochloride)IBA 10/2018 - 07/2007
5	AminesIBA 01/2015 - 12/2002
4	Liposomes (Liposome)IBA 06/2022 - 01/2010
4	Messenger RNA (mRNA)IBA 01/2019 - 06/2011
4	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 10/2002
3	pimonidazoleIBA 03/2024 - 07/2015
3	green 5IBA 01/2019 - 01/2013
3	azomycinIBA 01/2018 - 08/2013
3	EnzymesIBA 10/2015 - 03/2002
3	Cisplatin (Platino)FDA LinkGeneric 11/2014 - 01/2004
3	SolutionsIBA 11/2014 - 06/2004
3	NitrogenIBA 11/2014 - 11/2008
3	Nitro CompoundsIBA 12/2013 - 10/2009
3	LigandsIBA 07/2013 - 09/2004
3	CobaltIBA 07/2013 - 06/2006
3	cyclenIBA 07/2013 - 09/2004
3	tretazicarIBA 06/2004 - 03/2002
2	olaparibIBA 07/2023 - 12/2019
2	AcidsIBA 06/2022 - 07/2019
2	IC87361IBA 12/2019 - 11/2019
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 11/2019 - 01/2018
2	Small Interfering RNA (siRNA)IBA 01/2019 - 05/2012
2	Gemcitabine FDA Link 01/2019 - 07/2007
2	Glucose (Dextrose)FDA LinkGeneric 10/2018 - 01/2013
2	4-nitroimidazoleIBA 01/2018 - 04/2014
2	NitroimidazolesIBA 01/2018 - 04/2014
2	TriazinesIBA 01/2017 - 11/2008
2	Carbonic Anhydrase IXIBA 07/2015 - 01/2012
2	Sorafenib (BAY 43-9006)FDA Link 01/2015 - 08/2011
2	Proteins (Proteins, Gene)FDA Link 10/2014 - 05/2012
2	Zinc Finger NucleasesIBA 12/2013 - 01/2013
2	Adenosine Diphosphate (ADP)IBA 01/2013 - 05/2012
2	Adenine FDA LinkGeneric 01/2012 - 10/2009
2	SaltsIBA 01/2012 - 12/2002
2	DuocarmycinsIBA 08/2011 - 03/2011
2	nitromide (Unistat)IBA 03/2010 - 07/2007
2	3-amino-1,2,4-benzotriazine-1-oxideIBA 06/2004 - 01/2004
1	Temozolomide (Temodar)FDA LinkGeneric 07/2023
1	CalciumIBA 06/2022
1	Protons (Proton)IBA 06/2022
1	AZD7648IBA 01/2022
1	CopperIBA 10/2020
1	Hydroxyl RadicalIBA 10/2020
1	veliparibIBA 12/2019
1	8- dibenzothiophen- 4- yl- 2- morpholin- 4- yl- chromen- 4- oneIBA 12/2019
1	DNA-Activated Protein KinaseIBA 11/2019
1	formic acid (formate)IBA 11/2019
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 04/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2019
1	meropenem and vaborbactamIBA 01/2019
1	isophosphamide mustard (IPAM)IBA 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	imidazoleIBA 10/2018

Therapy/Procedure

16	Therapeutics 03/2024 - 03/2002
15	Radiotherapy 12/2021 - 01/2004
8	Drug Therapy (Chemotherapy) 04/2019 - 01/2003
4	Aftercare (After-Treatment) 08/2013 - 08/2006
1	Catheters 06/2024
1	Immunotherapy 01/2022
1	Critical Care (Surgical Intensive Care) 02/2021
1	Precision Medicine 01/2019
1	Chemoradiotherapy 01/2019